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Abstract
Background: We compared a novel assay for free light 
chain (FLC) quantitation based on monoclonal antibod-
ies (N-Latex, Siemens, Germany) to the established poly-
clonal antibody-based assay (Freelite™, The Binding Site, 
UK) in AL amyloidosis.
Methods: Sixty-two diagnostic samples were analysed on 
a BNII nephelometer, 32 of which also had a post-treat-
ment sample.
Results: In the diagnostic samples: for AL of κ type, the 
median involved FLC (iFLC) was significantly lower by the 
N-Latex assay (289 vs. 667 mg/L, p = 0.0002) whereas for 
λ AL the values were similar (148 vs. 161 mg/L, p = 0.84). 
Measurable disease, defined as a difference between 
involved and uninvolved FLC (dFLC)  > 50 mg/L was 
present in 82% by the N-Latex assay compared to 89% by 
the Freelite™ assay. For diagnostic sensitivity, the FLC ratio 
was normal in 21% (95% CI 12%–33%) and 15% (95% CI 
7%–26%) of patients by the N-Latex and Freelite™ assays, 
respectively. The combination of serum and urine immuno-
fixation electrophoresis with either FLC assay allowed 
identification of the amyloidogenic clone in 98% produc-
ing comparable sensitivity. For the monitoring samples 
the median reduction in dFLC was 68% for the N-Latex 
assay and 77% for the Freelite™ assay (p = 0.04). This led to 
some differences in assigning response categories. Partial 
response as assigned by both assays predicted overall sur-
vival (N-Latex p = 0.0015, Freelite™ p = 0.022).
Conclusions: There are differences between FLC as mea-
sured by the N-Latex and Freelite™ assays, but overall the 
two assays have similar diagnostic sensitivity. Disease 
response calculated by both assays predicts survival but 
more clinical validation is required.
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Introduction
Since its first description [1], the availability of a com-
mercial serum free light chain (FLC) assay (Freelite™, The 
Binding Site, UK) has been a major advance in the diagno-
sis and monitoring of AL amyloidosis. When the FLC assay 
is used in conjunction with serum and urine immunofixa-
tion electrophoresis, more than 95% of plasma cell clones 
can be detected at diagnosis, making this combination 
an essential part of the work-up of patients suspected to 
have AL amyloidosis [1–3]. Changes in the FLC concentra-
tion in response to therapy have been shown to predict 
both organ response and overall survival (OS) [1, 4–6]. The 
importance of the FLC assay in management of AL amy-
loidosis is now firmly established in consensus guidelines 
[7–9]. All of this clinical validation has been done with the 
Freelite™ assay.
Despite these important advances, the Freelite™ assay 
suffers from several analytical limitations. The polyclonal 
anti-FLC antibodies are obtained from sheep immunised 
against human Bence Jones protein and batch-to-batch 
variation in the polyclonal antisera used in the assay has 
been noted [10, 11]. The assay is also prone to non-linearity 
[10] leading to inaccurate quantitation and antigen excess 
[11] which can occasionally lead to misdiagnosis. This 
necessitates additional work and expense for the labo-
ratory when samples need to be retested at further dilu-
tions as recommended by the manufacturer. Rare samples 
do not react with the Freelite™ assay [10]. There are also 
reports that the antisera may cross react with κ and λ light 
chains that are bound to heavy chains leading to overes-
timation of the involved FLC [12]. These analytical limita-
tions demonstrate the need for assay improvement.
Recently, serum κ and λ FLC immunonephelomet-
ric assays based on monoclonal antibodies have become 
commercially available (N Latex FLC assay, Siemens) 
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[13]. This new FLC assay appears to have some analyti-
cal advantages over the Freelite™ assay [14] but lacks 
clinical validation, particularly in AL amyloidosis where 
FLC measurement has such a central and critical role in 
patient management. We assessed the utility of the N 
Latex FLC assays in the diagnosis and monitoring of AL 
amyloidosis and compared it with the polyclonal Freelite™ 
κ and λ FLC assays.
Materials and methods
Patient samples
Sixty-two patients with newly diagnosed biopsy proven systemic AL 
amyloidosis who had serum stored at diagnosis were retrospectively 
identified. Thirty-two of these patients also had a post-treatment 
serum sample available. These patients had presented to the Princess 
Alexandra Hospital Haematology Department or its recently estab-
lished Amyloidosis Clinic or were enrolled on a prospective clinical 
trial of risk-adapted intravenous melphalan [15]. Amyloid subtype 
was confirmed as follows: laser capture microdissection and tandem 
mass spectrometry (n = 13); immunohistochemistry or immunofluo-
rescence (n = 29); non-diagnostic immunohistochemistry with clonal 
light chain abnormality and consistent clinical history (n = 10); clini-
cal trial patient where subtyping method not known but there was 
a protocol requirement to exclude non-AL types of amyloid (n = 10). 
In the latter two categories the involved FLC was determined on the 
basis of the serum and urine protein immunofixation electrophore-
sis, bone marrow and FLC studies. In no case did these studies yield 
contradictory light chain restriction. Treatments received included: 
no therapy (n = 9); high-dose melphalan and autologous stem cell 
transplantation (n = 15); melphalan and dexamethasone (n = 26); 
cyclophosphamide, thalidomide and dexamethasone (n = 8); bort-
ezomib-based therapy (n = 3); and other (n = 1). Serum samples had 
been stored frozen at −80°C for up to 10 years (range 2–121 months) 
prior to analysis. Ethical approval for the study was obtained from 
the Metro South Human Research Ethics Committee.
Laboratory assays
Serum FLC were measured with two commercial reagent kits: Free-
lite™ (Human Kappa and Lambda Free kits; The Binding Site Ltd, 
Birmingham, UK) and N Latex FLC κ and λ assays (Siemens Healthcare 
Diagnostics, Marburg, Germany) on a Siemens BNII nephelometer. 
Freelite™ and N Latex FLC measurements were performed on the 
same days on the same thawed samples. All initial Kappa and Lamb-
da FLC assays were done at 1 in 100 sample dilution. For the Freelite™ 
assay the next higher dilution, 1 in 400, was also performed if Kappa 
FLC was  > 50 mg/L and below the upper measuring limit, or Lambda 
FLC was  > 100 mg/L and below the upper measuring limit, to detect 
samples exhibiting antigen excess and gross non-linearity. One AL 
sample exhibited antigen excess by Freelite™ Kappa FLC assay. For 
the sake of brevity, the respective analytical systems are referred to 
as Freelite™ and N Latex FLC hereafter. The diagnostic range for the 
Freelite™ κ/λ ratio was 0.26–1.65 and for the N Latex FLC κ/λ ratio 
was 0.31–1.56. Serum (and urine) protein immunofixation electropho-
resis were not repeated on the stored sera, but the results from the 
routine clinical analysis at the time of sample collection were used. 
For the most part, these were performed on Hydrasys gel systems 
(Sebia, France).
Definitions
Median diagnostic values from the current study were used to di-
chotomise the continuous variable, difference between the involved 
and uninvolved FLC (dFLC), in assessment of its prognostic value: 
150 mg/L for N Latex assay and 190 mg/L for Freelite assay. Disease 
considered “measurable” for response was defined as having a 
dFLC  > 50 mg/L. Assessment of haematological response was defined 
according to the recently published response criteria [16]. In brief, 
the dFLC was calculated for all diagnostic and post-treatment sam-
ples. Response criteria were defined as follows: partial response (PR) 
–  > 50% reduction in the dFLC; very good partial response (vgPR) – 
reduction in the dFLC to  < 40 mg/L; a complete response (CR) – nor-
malisation of the free light chain ratio, negative serum and urine im-
munofixation electrophoresis.
Statistical analysis
Method comparison was performed using Passing-Bablok regression 
and Bland-Altman plots with Analyse-It (Version 2.21) and Method 
Validator software packages. Continuous variables were compared 
using the Wilcoxon rank sum test. The correlation between survival 
and FLC response was studied using Kaplan-Meier analysis and the 
curves were compared using the log-rank test. These latter statisti-
cal analyses were performed using the STATA (University of Texas) 
statistical software package.
Results
Diagnostic sensitivity
Of the diagnostic samples, 18 patients had amyloid of κ 
type and 44 had amyloid of λ type. The diagnostic sensi-
tivity of the two FLC assays is shown in Table 1. The FLC 
ratio was normal in 21% (95% CI 12%–33%) and 15% (95% 
CI 7%–26%) of patients by the N Latex assay and Freelite™ 
assays, respectively. This difference was not significant 
(p = 0.3). Both FLC assays showed abnormal FLC ratios for 
all 18 patients with κ light chain amyloidosis. In patients 
with λ light chain amyloidosis, however, the FLC ratio was 
abnormal in 31/44 by the N Latex FLC and 35/44 by the 
Freelite™ assay. In this λ group, both assays showed an 
abnormal FLC ratio in 29 cases, both ratios were normal 
in seven cases, in two cases the N Latex FLC ratio was 
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abnormal and the Freelite™ was normal, and in six cases 
the N Latex FLC ratio was normal and the Freelite™ was 
abnormal. The combination of serum and urine IFE with 
either FLC assay, however, allowed identification of the 
amyloidogenic clone in 98% producing comparable sen-
sitivity for both methods.
Comparison of baseline FLC concentrations
For patients with amyloidosis of κ type the median 
involved FLC (iFLC) was significantly lower by the N Latex 
assay (289 vs. 667 mg/L, p = 0.0002) whereas in amyloi-
dosis of λ type the values were similar (148 vs. 161 mg/L, 
p = 0.84). According to current consensus criteria 82% of 
AL amyloidosis would be measurable by the N Latex assay 
compared to 89% by the Freelite™ assay. As a prognostic 
factor, a higher dFLC predicted worse OS whether meas-
ured by the N latex (2 yr OS 22% vs. 67%, p = 0.0041) or 
Freelite™ assay (2 yr OS 20% vs. 69%, p = 0.0005) (Figure 1).
Monitoring utility
For the 32 patients with monitoring samples the post-treat-
ment sample was taken at a median of 4 months (range 
1–12 months) post-initiation of chemotherapy. The median 
follow-up of survivors in this group was 50 months. The 
median reduction in dFLC was 68% (range, 35% increase 
to 100% reduction) for the N Latex assay and 77% (range, 
7% increase to 100% reduction) for the Freelite™ assay 
(p = 0.04). By current consensus criteria, more patients had 
measurable disease by the Freelite™ assay (n = 29) than by 
the N Latex assay (n = 25). This led to some differences in 
assigning response categories. The response according 
Table 1 Diagnostic sensitivity of immunofixation electrophoresis and either N Latex FLC or Freelite™ κ/λ ratio in 62 patients with AL 
amyloidosis.
n κ light chain amyloid (95% CI) λ light chain amyloid  (95% CI) All patients (95% CI)
18 44 62
Serum IFE 56% (31%–78%) 73% (57%–85%) 68% (55%–79%)
Urine IFE 89% (65%–97%) 80% (65%–90%) 82% (70%–91%)
Serum and urine IFE 89% (65%–97%) 89% (75%–96%) 89% (78%–95%)
N Latex FLC
 κ/λ ratio 100% (81%–100%) 70% (55%–83%) 79% (67%–88%)
 κ/λ ratio+serum and urine IFE 100% (81%–100%) 98% (88%–100%) 98% (91%–100%)
Freelite™
 κ/λ ratio 100% (81%–100%) 80% (65%–90%) 85% (74%–93%)
 κ/λ ratio+serum and urine IFE 100% (81%–100%) 98% (88%–100%) 98% (91%–100%)
CI, confidence interval; IFE, immunofixation electrophoresis; FLC, serum free light chain.
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Figure 1 Overall survival according to difference in involved and 
uninvolved FLC (dFLC) at baseline for: (A) N Latex FLC assay and (B) 
FreeliteTM FLC assay.
to the N Latex assay (n = 25) was: CR (16%), vgPR (32%), 
PR (12%), no response (40%). The response according 
to the Freelite™ assay (n = 29) was: CR (7%), vgPR (38%), 
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PR (17%), no response (38%). Concordance of response 
categories according to the two assays in patients with 
measureable disease by both assays (n = 24) are detailed 
in Table 2. In those patients with measurable disease, a 
partial remission predicted OS by the N Latex (n = 25, 2 yr 
OS 82% vs. 27%, p = 0.0015) and Freelite™ assays (n = 29, 2 
yr OS 75% vs. 36%, p = 0.02) (Figure 2).
Analytical comparison
For an analytical method comparison FreeliteTM and N 
Latex FLC concentrations and K/L ratio were compared 
by Passing-Bablok regression analysis for the 94 sample 
results (Figure 3) and by Bland-Altman plot for mean differ-
ence (Figure 4). While there is good agreement between the 
Lambda FLC concentrations as measured by both assays, 
there was bias in the measurement of Kappa FLC concen-
tration. The FreeliteTM assay gave lower values at low FLC 
concentrations ( < 10 mg/L) and higher values at high FLC 
concentrations ( > 75 mg/L) compared to the N Latex 
FLC assay. This was explored further by examining the 
Bland-Altman plot according to whether the measurand 
was the involved versus non-involved FLC. This demon-
strates that the FreeliteTM assay is giving lower values for 
the non-involved polyclonal κ light chain and higher values 
for the monoclonal involved κ light chain (Figure 4). While 
this tendency was less marked for the Lambda FLC com-
parison, the uninvolved Lambda FLC concentrations gen-
erally were lower by FreeliteTM compared to the N Latex FLC 
assay (Figure 4). Table 3 summarises the Passing-Bablok 
regression slope for the κ and λ assays in this study of AL 
amyloidosis compared to a more general hospital popula-
tion [14]. In AL amyloidosis where the measured FLC cor-
responded to that involved by the AL disease process the 
slope is significantly lower compared to the uninvolved 
FLC as the 95% confidence intervals do not overlap.
An analysis of batch-to-batch variation was also per-
formed. Of the 59 ratios that were available for comparison 
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Figure 2 Overall survival according to FLC response for: (A) N Latex 
FLC assay and (B) FreeliteTM FLC assay.
Table 2 Response category among 24 patients with AL amyloidosis 
with measurable disease by both N Latex FLC and Freelite™ assays.
N Latex FLC response
CR vgPR PR NR
Freelite™ response CR 2 0 0 0
vgPR 0 5 2 1
PR 1 2 1 1
NR 0 1 0 8
CR, complete response; NR, no response; PR, partial response; 
vgPR, very good partial response.
to previous results obtained over different batches of 
FreeliteTM reagent over 10 years, there were eight different 
assignments by FreeliteTM (5 abnormal κ/λ ratios changed 
to normal ratios; 3 normal ratios changed to abnormal 
ratios) and a 13.6% difference in κ/λ ratio assignment. 
The between-reagent variation was greater for FreeliteTM 
Kappa FLC [PB slope: 1.237 (95% CI 0.934−1.468)] whereas 
FreeliteTM Lambda FLC was better correlated [PB slope: 
1.044 (95% CI 0.988−1.096] to previous reagent lots.
Discussion
In terms of diagnostic sensitivity, we demonstrated that 
the FLC κ/λ ratio was abnormal in 79% and 85% of AL 
amyloid cases when measured by the N Latex FLC and 
Freelite™ assays, respectively. This non-significant diffe-
rence was due to fewer cases of λ light chain amyloid 
having an abnormal κ/λ ratio by the N Latex FLC assay. 
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Thus, the N Latex and Freelite™ assays “miss” 13 and 
nine cases of AL amyloidosis, respectively. The routine 
screening for AL amyloidosis, however, consists of the 
combination of serum and urine IFE with the FLC assay. 
This combination, using either FLC assay, allowed identi-
fication of the amyloidogenic clone in 98% producing 
comparable sensitivity for both methods. These results 
are very similar to those presented by Palladini et al. [17] 
where 338 patients with newly diagnosed AL amyloidosis 
were assessed. In this report the κ/λ ratio was abnormal 
in 84% and 82% of AL cases when measured by the N 
Latex FLC and Freelite™ assays, respectively. When either 
FLC assay was combined with serum and urine IFE, 98% 
of cases were detected providing confirmatory evidence 
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Figure 3 N Latex and Freelite™ FLC assay method comparisons in AL 
amyloidosis.
Grey line is line of identity; dotted line is Passing-Bablok regression 
line on a logarithmic scale.
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Figure 4 Bland-Altman difference plots in AL amyloidosis.
Solid line is mean difference; dotted lines are 95% confidence inter-
vals at zero mean difference; closed circles represent uninvolved 
(polyclonal) FLC values; open circles represent involved (monoclo-
nal) FLC values.
of the diagnostic sensitivity of the N Latex assay for AL 
amyloidosis.
As reported with the Freelite™ assay [18], we found 
that the absolute level of the dFLC at diagnosis was pre-
dictive of outcome with higher levels associated with 
worse OS. In comparing the two FLC assays the median 
dFLC levels in our study were very similar to those from 
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the Pavia Amyloidosis Research and Treatment Center 
[17]: 150 mg/L vs. 165 mg/L for the N Latex FLC assay and 
190 mg/L vs. 180 mg/L for the Freelite™ assay.
In the monitoring context, we found that slightly 
fewer patients had measurable disease (defined as dFLC 
 > 50 mg/L) when using the N Latex FLC assay results (82% 
vs. 89%). In Palladini’s study 75% of patients had measur-
able disease as assessed by either assay although only 64% 
had baseline dFLC  > 50 mg/L by both assays. These “meas-
urable disease” criteria are based on studies using the 
Freelite™ assay. Given the analytical differences between 
the two assays, it may be that consensus guidelines will 
need to consider different cut-offs for different assays or a 
single cut-off that balances both assay’s monitoring preci-
sion with the need to have as many patients with measur-
able disease as possible. Our sample size was too small to 
address these issues. While response categories as calcu-
lated using either assay results were broadly similar there 
were some differences, particularly in the partial remis-
sion category. Again, our findings were similar to those of 
Palladini’s larger study. Due to the small sample size, we 
were only able to examine the impact of partial response 
or better (includes CR, vgPR and PR) on survival with both 
assays significantly predicting outcome.
The analytic comparison demonstrated differences 
between the two assays, particularly in the measurement 
of the Kappa FLC. In particular, these differences related 
to whether the FLC being measured was the involved FLC 
(comprising predominantly the amyloidogenic FLC plus 
smaller amounts of polyclonal FLC of same isotype) or 
the uninvolved polyclonal FLC. Thus, the amyloidogenic 
light chain is reacting differently in one or both assays 
to the polyclonal light chains of the same isotype. Due to 
the lack of standards for immunoglobulin light chains, it 
is difficult to determine which assay is over-estimating 
(or under-estimating) the true FLC value. These differ-
ences in involved FLC values between assays may be due 
to non-parallel immunoreactivity between the calibra-
tor (polyclonal) and the samples (monoclonal) in one or 
both assays possibly due to limited antigenicity of the 
amyloid molecule and a unique amino acid sequence 
in the variable region. Lot-to-lot variation of polyclonal 
antibody-based FreeliteTM reagent may contribute to some 
of the difference as demonstrated by the comparison of 
FLC ratios in the current study compared to that obtained 
initially with a different reagent lot. Campbell et  al. [19] 
describe the presence of “gaps” at low FLC concentra-
tion when FreeliteTM was compared with monoclonal FLC 
antibody assays and that these may contribute to falsely 
elevated FLC ratio. Figure 3 highlights there is a difference 
between the two methods at low concentrations below 10 
mg/L FLC, in particular for Kappa FLC.
Differences between the two assays may also reflect 
the subject group evaluated, e.g., AL group versus a 
more heterogeneous hospital population [14] (Table 3) 
or the FLC concentration. This demonstrates the impor-
tance of performing analytic validation studies in differ-
ent light chain disease populations rather than just in 
general hospital or normal donor populations. Further, 
the study demonstrates that there are differences in 
absolute values between FreeliteTM and N Latex such that 
values cannot be used interchangeably when monitoring 
disease response in AL amyloidosis or other monoclonal 
light chain diseases. Rather, clinicians should monitor 
FLC using the same manufacturer’s assay on the same 
instrument.
Our study does present some limitations. Our sample 
size is relatively small, especially for the monitoring 
group, so conclusions must be made with caution. None-
theless, the consistency of the findings with the only 
other study in the field lends support to the conclusions. 
The study is also retrospective in nature, treatment was 
not standardised across the patient cohort, and the post-
treatment serum sample was only available on a subset 
of patients and was not taken at a uniform timepoint. All 
these factors can potentially introduce bias into the study 
but should not significantly affect the comparison of the 
two FLC assays.
Table 3 Passing-Bablok regression slope and 95% confidence intervals (CI) for κ and λ free light chains (FLC) assays.
Subject group, n κ FLC measurand λ FLC measurand
Total, involved or uninvolved FLC Slope (95% CI) Slope (95% CI)
AL amyloidosis [this study]
 Total (n = 94) 0.71 (0.65–0.83) 1.07 (0.92–1.22)
 Involved (monoclonal) FLC (26 κ, 68 λ) 0.58 (0.45–0.65) 1.02 (0.82–1.24)
 Uninvolved (polyclonal) FLC (68 κ, 26 λ) 1.16 (1.06–1.29) 2.11 (1.70–2.61)
Hospital population [14]
 Total (polyclonal and monoclonal) FLC (n = 116) 1.36 (1.22–1.54) 1.37 (1.26–1.50)
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In summary, we assessed the new N Latex FLC 
assay in the diagnosis and monitoring of patients with 
AL amyloidosis. The new assay appears to have similar 
diagnostic, prognostic and monitoring utility compared 
to the established Freelite™ assay but further prospec-
tive validation in larger cohorts of patients is required 
to confirm these findings and support the introduction 
of the N Latex assay into clinical practice for this group 
of patients. Importantly, in the changeover from one 
manufacturer’s FLC (or any tumour marker) assay to 
another manufacturer’s assay there should be a lengthy 
overlap period where FLC are measured by both assays 
when monitoring patients with previously diagnosed 
disease. This enables the clinician to become famil-
iar with any differences in absolute numbers between 
assays.
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